CAPR Quote, Financials, Valuation and Earnings

AIM ImmunoTech has a net margin of -555.2% compared to Capricor Therapeutics's net margin of -10571.43%. Capricor Therapeutics's return on equity of -143.31% beat AIM ImmunoTech's return on equity of -256.33%.

Capricor Therapeutics has a consensus price target of --, signalling upside risk potential of 193.22%. On the other hand AIM ImmunoTech has an analysts' consensus of -- which suggests that it could grow by 1268.16%. Given that AIM ImmunoTech has higher upside potential than Capricor Therapeutics, analysts believe AIM ImmunoTech is more attractive than Capricor Therapeutics.

Capricor Therapeutics has a beta of 3.980, which suggesting that the stock is 298.019% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of -0.363, suggesting its less volatile than the S&P 500 by 136.304%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $2.3M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Capricor Therapeutics's net income of -$12.6M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 19.24x versus 55.24x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

ICU Medical has a net margin of -555.2% compared to Capricor Therapeutics's net margin of -5.6%. Capricor Therapeutics's return on equity of -143.31% beat ICU Medical's return on equity of -5.35%.

Capricor Therapeutics has a consensus price target of --, signalling upside risk potential of 193.22%. On the other hand ICU Medical has an analysts' consensus of $142.25 which suggests that it could grow by 30%. Given that Capricor Therapeutics has higher upside potential than ICU Medical, analysts believe Capricor Therapeutics is more attractive than ICU Medical.

Capricor Therapeutics has a beta of 3.980, which suggesting that the stock is 298.019% more volatile than S&P 500. In comparison ICU Medical has a beta of 0.623, suggesting its less volatile than the S&P 500 by 37.74%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. ICU Medical pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $2.3M, which are smaller than ICU Medical quarterly revenues of $589.1M. Capricor Therapeutics's net income of -$12.6M is higher than ICU Medical's net income of -$33M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while ICU Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 19.24x versus 1.62x for ICU Medical. Usually stocks with elevated PS ratios are considered overvalued.

enVVeno Medical has a net margin of -555.2% compared to Capricor Therapeutics's net margin of --. Capricor Therapeutics's return on equity of -143.31% beat enVVeno Medical's return on equity of --.

Capricor Therapeutics has a consensus price target of --, signalling upside risk potential of 193.22%. On the other hand enVVeno Medical has an analysts' consensus of -- which suggests that it could grow by 488.24%. Given that enVVeno Medical has higher upside potential than Capricor Therapeutics, analysts believe enVVeno Medical is more attractive than Capricor Therapeutics.

Capricor Therapeutics has a beta of 3.980, which suggesting that the stock is 298.019% more volatile than S&P 500. In comparison enVVeno Medical has a beta of 1.219, suggesting its more volatile than the S&P 500 by 21.904%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $2.3M, which are larger than enVVeno Medical quarterly revenues of --. Capricor Therapeutics's net income of -$12.6M is lower than enVVeno Medical's net income of -$5.6M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 19.24x versus 260.98x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -555.2% compared to Capricor Therapeutics's net margin of 25.43%. Capricor Therapeutics's return on equity of -143.31% beat ResMed's return on equity of 23.76%.

Capricor Therapeutics has a consensus price target of --, signalling upside risk potential of 193.22%. On the other hand ResMed has an analysts' consensus of $206.05 which suggests that it could grow by 8.22%. Given that Capricor Therapeutics has higher upside potential than ResMed, analysts believe Capricor Therapeutics is more attractive than ResMed.

Capricor Therapeutics has a beta of 3.980, which suggesting that the stock is 298.019% more volatile than S&P 500. In comparison ResMed has a beta of 0.684, suggesting its less volatile than the S&P 500 by 31.593%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.86% to investors and pays a quarterly dividend of $0.53 per share. Capricor Therapeutics pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Capricor Therapeutics quarterly revenues are $2.3M, which are smaller than ResMed quarterly revenues of $1.2B. Capricor Therapeutics's net income of -$12.6M is lower than ResMed's net income of $311.4M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while ResMed's PE ratio is 30.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 19.24x versus 7.18x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.